Eptifibatide and ST Segment Resolution Following Primary PCI

Inclusion Criteria: * Patients \>18 years old * Patients with acute myocardial infarction whose symptom onset is within 12 hours of presentation * ST-segment elevation 1 mm in 2 contiguous limb leads or 2 mm in 2 contiguous precordial leads * Patients eligible for PCI * Target lesion(s) in a native vessel * Target lesion stenosis \>50% by angiography (visual estimate) * Patients who are amenable to participating in study procedures and follow-up * Patient or legal guardian has been informed and agrees to provide approved written informed consent and data privacy authorization Exclusion Criteria: * Patients with cardiogenic shock (SBP\<80 mmHg for \>30 minutes or requiring pressors or IABP due to hypotension) * Patients with cardiac arrest at any point prior to intervention (within the preceeding 24 hours) * Patients on chronic warfarin (Coumadin) therapy * Patients with known bleeding diathesis or active bleeding at the time of presentation to the catheterization laboratory * Patients with known bleeding diathesis or active bleeding within prior 3 months * Patients who receive thrombolytic therapy or glycoprotein IIb/IIIa inhibitors prior to PCI (within the preceding 8 hours) * Patients with a platelet count \<100,000 cells/mm3 within the preceeding 7 days * Patients with known allergies to aspirin, clopidogrel bisulfate (Plavix), heparin, bivalirudin, glycoprotein IIb/IIIa inhibitors or intravenous contrast dye that cannot be medically managed * Patients with major surgery within the past 6 months or scheduled surgery within 6 weeks * Patients with significant unprotected left main disease (stenosis \>60%) or with multivessel coronary disease that will require emergent coronary artery bypass surgery * Patients with TIA or CVA within the past 30 days or any history of hemorrhagic stroke * Patients who have undergone PCI within the preceding 30 days prior to enrollment * Patients with known impaired renal function * Patient is know to be pregnant or lactating * Patients with active participation in another device or drug study * Patients with comorbidities conferring a life expectancy of less than a year * Patients with left bundle branch block